ChromaDex Corp (CDXC)

3.53
0.03 0.84
NASDAQ : Health Care
Prev Close 3.56
Open 3.59
Day Low/High 3.52 / 3.63
52 Wk Low/High 2.46 / 6.18
Volume 97.24K
Avg Volume 416.70K
Exchange NASDAQ
Shares Outstanding 46.09M
Market Cap 169.16M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ChromaDex Appoints Harvard Medical School Professor Of Neurology, Dr. Rudolph Tanzi, To The Scientific Advisory Board

Global Alzheimer's Thought Leader to Assist in Exploring Potential for Nicotinamide Riboside in Brain and Neuronal Health

Short Interest Moves 12.5% Higher For CDXC

The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 307,817 share increase in total short interest for ChromaDex Corp , to 2,763,960, an increase of 12.53% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

ChromaDex Names World's Leading Expert On Nicotinamide Riboside And NAD As Chief Scientific Advisor

Charles Brenner, PhD, an investigator on the forefront of metabolism research, to champion the advancement of NR and NAD boosting technologies

NIAGEN® Nicotinamide Riboside Launches Into The Functional Food Space

Barology's Live Younger™ bar offers consumers a new way to help boost cellular metabolism and cellular energy production

ChromaDex Reports First Quarter 2017 Financial Results

Changes in Q1 and new investor set the foundation for success with NIAGEN®

ChromaDex To Report First Quarter 2017 Financial Results On Thursday, May 11, 2017

Company Will Host Investor Conference Call on Thursday, May 11, 2017

ChromaDex Reports 2016 Record Revenue As Ingredient Sales Grew 34%

Q4 Total Revenue Increased 29% and 2016 Total Revenue Increased 22%

ChromaDex To Report Year End 2016 Financial Results On Thursday, March 16, 2017

Company Will Host Investor Conference Call on Friday, March 17, 2017

Study Published In PAIN Reveals Nicotinamide Riboside Is An Effective Tool In Relieving Chemotherapy-Induced Peripheral Neuropathy Induced By A Common Anticancer Agent

Early findings demonstrated in female rats may one day lead to reductions in the neuropathic pain experienced by millions of breast and ovarian cancer patients and survivors

ChromaDex Expects To Report Record Fourth Quarter As Revenue Increased Approximately 29%

Q4 2016 Revenue is Expected to be Approximately $5.6 Million with Full-Year 2016 Revenue of Approximately $26.8 million

ChromaDex Opens New State-of-the-Art Research And Development Center In Longmont

ChromaDex Opens New State-of-the-Art Research And Development Center In Longmont

R&D Facility an Important Milestone for ChromaDex to Continue Global Leadership in the Identification and Development of NAD+ Metabolites

ChromaDex Names Dr. Matthew Roberts As A New Scientific Advisory Board Member

ChromaDex Names Dr. Matthew Roberts As A New Scientific Advisory Board Member

Company's Scientific Advisory Board Will Be Comprised of a Diverse Range of Experts with an Emphasis on Nicotinamide Riboside

ChromaDex To Report Third Quarter 2016 Financial Results On Thursday, November 10, 2016

ChromaDex To Report Third Quarter 2016 Financial Results On Thursday, November 10, 2016

Company Will Host Investor Conference Call on Thursday, November 10, 2016